Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
LIV | Ann: LIV NTA 03-10-2024 $2.91488 | 07:34 | 0 | 20 | |||
|
|||||||
LIV | Ann: LIV NTA 02-10-2024 $2.89021 | 03/10/24 | 0 | 36 | |||
|
|||||||
LIV | Ann: LIV NTA 01-10-2024 $2.87833 | 02/10/24 | 0 | 43 | |||
|
|||||||
LIV | Ann: LIV NTA 30-09-2024 $2.89688 | 01/10/24 | 0 | 28 | |||
|
|||||||
LIV | Ann: LIV NTA 27-09-2024 $2.87993 | 30/09/24 | 0 | 33 | |||
|
|||||||
LIV | Ann: LIV NTA 26-09-2024 $2.88510 | 27/09/24 | 0 | 41 | |||
|
|||||||
LIV | Ann: LIV NTA 25-09-2024 $2.90325 | 26/09/24 | 0 | 36 | |||
|
|||||||
LIV | Ann: LIV NTA 24-09-2024 $2.94046 | 25/09/24 | 0 | 54 | |||
|
See All Discussions